TX-PHILLIPS-66
19.7.2022 15:02:13 CEST | Business Wire | Pressemeddelelse
Phillips 66 (NYSE: PSX) og H2 Energy Europe ("H2 Energy") meddelte i dag, at de har indgået en 50-50 joint venture-aftale med henblik på etablering og drift af et netværk af brinttankstationer og skabelsen af et grønt brintøkosystem i Tyskland, Østrig og Danmark.
JET H2 Energy Austria GmbH (JET H2 Energy), som udgør joint venture-aftalen mellem datterselskaberne Phillips 66 Limited og H2 Energy Europe SA, forener Phillips 66's store ekspertise inden for detailhandel med H2 Energys erfaringer og ekspertise inden for brint. JET H2 Energy bliver en central aktør i branchen og vil sætte skub i udviklingen af brint som brændstof i Europa. Det nye selskab planlægger at etablere cirka 250 brinttankstationer inden 2026.
"Det er vores mål at gøre brint til en førende energibærer inden for emissionsfri mobilitet. Vi vil skabe ligevægt i de involverede aktørers interesser i hele brintværdikæden og skabe et bæredygtigt brintøkosystem,” udtaler Olaf Borbor, administrerende direktør for JET H2 Energy.
"Phillips 66 er med stor succes til stede på detailmarkedet i Europa med sit brand JET® . H2 Energy har en dokumenteret track record inden for skabelsen af et vellykket grønt brintøkosystem i Schweiz. Parternes kompetencer supplerer derfor hinanden ideelt i den næste fase i udviklingen af brintøkonomien."
JET H2 Energy vil søge og udvælge steder (greenfield-udvikling, JET® og kundesteder), etablere og drive brinttankstationer til både tunge og lette køretøjer og personbiler (FCEV'er), forsyne brinttankstationerne med grøn brint og opbygge relationer med kunder og originaludstyrsproducenter.
JET H2 Energy vil drage fordel af sit tætte samarbejde med Hyundai Hydrogen Mobility, der er eksklusiv europæisk forhandler af Hyundai Xcient-brintbrændselscellelastbilen.
Ledelsesteamet består af Olaf Borbor (CEO), Markus Wolf (CFO) og Jonas Erdmann (Commercial Manager). Det tyske hovedkvarter er baseret i Hamborg.
Phillips 66 Limited er en kombineret energiproduktions- og logistikvirksomhed hjemhørende i Storbritannien. Virksomheden er et datterselskab under og 100 % ejet af Phillips 66. Phillips 66 har med flere end 1.000 JET® -stationer en stærk tilstedeværelse på markedet i Europa og via joint venture-samarbejdet Coop Mineraloel AG et voksende netværk til optankning af brint i Schweiz.
H2 Energy Europe med hovedsæde i Schweiz er et joint venture mellem selskabet Trafigura Pte Ltd., der handler med råvarer, og H2 Energy Holding AG, en førende brintleverandør i Europa med investeringer i produktion, distribution og anvendelse af grøn brint. H2 Energy var gennem sine tilknyttede selskaber den første til at udvikle og levere brintbrændselscellelastbiler til kommercielle brugere og skabe et grønt brintbrændstof-økosystem i Schweiz.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220718005806/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum